Antonarakis et al. reported that the detection of AR-V7 in circulating tumor cells was predictive of resistance to enzalutamide and abiraterone. Some patients with undetectable AR-V7 at baseline subsequently converted to AR-V7-positive status during the course of treatment, suggesting that perhaps AR-V7 could serve as a dynamic biomarker to detect acquired resistance. What were the durations of response and the clinical courses of the men after they tested positive for AR-V7?
展开▼
